Trial Profile
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Bifikafusp alfa/onfekafusp alfa (Primary) ; Ipilimumab
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms NeoDREAM
- Sponsors Philogen
- 28 Mar 2023 According to a Philogen media release, patient enrolment in the US Phase III study in Stage IIIB/C melanoma continues in line with company plans. As of the date of this press release, 30 centres have been opened (19 in 2022, 5 in 2023). Additional centres will be opened during 2023.
- 20 Dec 2021 Planned End Date changed from 1 Dec 2024 to 1 Jun 2026.
- 20 Dec 2021 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.